BLAZE-1 Study is evaluating a potential COVID-19 antibody treatment following successful laboratory studies.
COLUMBUS, OH, September 02, 2020 /Neptune100/ — Aventiv Research announced today it has begun recruiting and treating patients in a clinical research study to evaluate the safety and effectiveness of LY-CoV555 in patients with early mild to moderate COVID-19. Sponsored by Eli Lilly and Company (Lilly), the BLAZE-1 Study is looking for adults ages 18 or older who have recently tested positive for COVID-19 and are not hospitalized.
LY-CoV555 is an antibody therapy engineered from one of the first individuals to recover from COVID-19, which may help newly diagnosed patients clear the SARS-CoV-2 virus faster. Laboratory studies have shown that LY-CoV555 binds with high affinity to the SARS-CoV-2 virus and neutralizes its ability to infect cells and replicate.
“Clinical trials like BLAZE-1 are vital in testing potential treatments for COVID-19 which, if successful, represent medicines which can be used to protect those most at risk of severe illness, such as the elderly and immunocompromised,” said Dr. Samir Arora, President & Medical Director of Aventiv Research. “Aventiv has been on the front lines of the fight against COVID-19, and we are honored to participate in this important, landmark study with Lilly to potentially bring effective COVID-19 treatment to the public faster.”
To be eligible for the BLAZE-1 Study, participants must have tested positive for SARS-CoV-2 infection within three days prior to the study drug infusion, and have one or more mild or moderate COVID-19 symptoms, including, fever, cough, sore throat, headache, muscle pain, nausea, abdominal pain, diarrhea, or shortness of breath when active.
If a person is eligible and decides to participate, the research staff at Aventiv Research will perform specific tests and procedures to monitor the patient’s health and how their body reacts to the LY-CoV555 antibody treatment. These tests and procedures include physical exams, vital sign measurements, blood samples, and nasopharyngeal swabs to measure levels of virus.
The study drug is being compared to a placebo, and both the study drug and the placebo will be administered as a single-dose intravenous (IV) infusion. Participants will be randomly selected to receive the placebo or the study drug.
“Kicking off the BLAZE-1 Study with research sites around the country, including Aventiv Research is a huge milestone for the global fight against COVID-19, and we’re excited to bring the industry one step closer to a potential treatment,” said Dr. Daniel Skovronsky, chief scientific officer, Eli Lilly and Company. “We look forward to working with eligible patients who are not only interested in receiving investigational treatments for COVID-19, but who also understand how their participation can impact the health and well-being of millions of people around the world.”
BLAZE-1 Study participants will be seen at Aventiv’s main clinical pharmacology site located in Columbus at 99 N. Brice Road, Suite 260, neighboring Mount Carmel East. The research center has been modified to offer COVID-19 positive patients’ touchless entry through a private entrance. A dedicated patient exam room and restroom will receive electrostatic cleaning between patient visits while clinical staff disrobe in a transition room to avoid cross contamination. Free parking is available.
If someone has tested positive and exhibited symptoms for COVID-19, and are interested in participating in clinical research in their area, call 614.501.6164 or visit AventivResearch.com to learn more.
About Aventiv Research
Aventiv Research exists to make novel medicines accessible to its patients and deliver industry-best pharmaceutical data to its sponsors. Its mission is to enrich the lives of both its team members and patients by putting medical research to work. Currently operating in two states with four independent research sites, Aventiv specializes in phase I-IV pharmaceutical, device, and diagnostic clinical trials in a variety of therapeutic areas. Built on the core values of dedication, integrity, resourcefulness, and professionalism, the company embraces a visionary, entrepreneurial spirit that compels its ambassadors to blaze new trails with proprietary systems and processes.
Founded in 2007 by Dr. Samir Arora, a proven leader with more than 15 years of clinical research experience, Aventiv Research has conducted over 450 clinical trials with more than 55 pharmaceutical sponsors and has helped 15 drugs to become approved by the FDA and available for use.